C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study

The Lancet - Early Online Publication, 02/07/2011

Evidence from this large–scale randomised trial does not lend support to the hypothesis that baseline C–reactive protein (CRP) concentration modifies the vascular benefits of statin therapy materially.

Go to Abstract Print Article Summary